In the case of OHSS risk, the use of oral medroxyprogesterone acetate was compared to the use of ant-GnRH in patients with polycystic ovary syndrome in a prospective controlled study. The gene discussed is GNRH1; the disease is ovarian hyperstimulation syndrome.